Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
Nadège Néant, Guillaume Lingas, Quentin Le Hingrat, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 8
Open Access | Times Cited: 218

Showing 26-50 of 218 citing articles:

SERS-PCR assays of SARS-CoV-2 target genes using Au nanoparticles-internalized Au nanodimple substrates
Yixuan Wu, Hajun Dang, Sung‐Gyu Park, et al.
Biosensors and Bioelectronics (2021) Vol. 197, pp. 113736-113736
Open Access | Times Cited: 42
Sensitivity of Reverse Transcription Polymerase Chain Reaction Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Through Time
Rachelle N. Binny, Patricia Priest, Nigel French, et al.
The Journal of Infectious Diseases (2022) Vol. 227, Iss. 1, pp. 9-17
Open Access | Times Cited: 34
Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Chapin S. Korosec, Suzan Farhang‐Sardroodi, David W. Dick, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 34
Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity
Jonah Lin, Ryan Law, Chapin S. Korosec, et al.
Journal of Virology (2022) Vol. 96, Iss. 13
Open Access | Times Cited: 30
Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms
Budhaditya Chatterjee, Harshbir Singh Sandhu, Narendra M. Dixit
PLoS Pathogens (2022) Vol. 18, Iss. 6, pp. e1010630-e1010630
Open Access | Times Cited: 29
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
Manaf AlQahtani, Nitya Kumar, Dhuha Aljawder, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2
Chrysovalantis Voutouri, C. Corey Hardin, Vivek Naranbhai, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 3
Open Access | Times Cited: 18
Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors
Pranesh Padmanabhan, Narendra M. Dixit
Journal of Theoretical Biology (2023) Vol. 572, pp. 111568-111568
Open Access | Times Cited: 16
Monkeypox: a review of epidemiological modelling studies and how modelling has led to mechanistic insight
Marina Banuet-Martínez, Yang Yang, Behnaz Jafari, et al.
Epidemiology and Infection (2023) Vol. 151
Open Access | Times Cited: 15
A Bayesian framework for modeling COVID‐19 case numbers through longitudinal monitoring of SARS‐CoV‐2 RNA in wastewater
Xiaotian Dai, Nicole Acosta, Xuewen Lu, et al.
Statistics in Medicine (2024) Vol. 43, Iss. 6, pp. 1153-1169
Open Access | Times Cited: 5
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
Phrutsamon Wongnak, William HK Schilling, Podjanee Jittamala, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 9, pp. 953-963
Open Access | Times Cited: 5
Defining the Critical Requisites for Accurate Simulation of SARS‐CoV‐2 Viral Dynamics: Patient Characteristics and Data Collection Protocol
H.C. Chua, Ananya Singh, Yuqian Wang, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 1
Open Access
SARS‐CoV‐2 virulence evolution: Avirulence theory, immunity and trade‐offs
Samuel Alizon, Mircea T. Sofonea
Journal of Evolutionary Biology (2021) Vol. 34, Iss. 12, pp. 1867-1877
Open Access | Times Cited: 37
Daily sampling of early SARS-CoV-2 infection reveals substantial heterogeneity in infectiousness
Ruian Ke, Pamela P. Martinez, Rebecca L. Smith, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 34
Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
Hernando Gaitán-Duarte, Carlos Álvarez, Carlos Rincón, et al.
EClinicalMedicine (2021) Vol. 43, pp. 101242-101242
Open Access | Times Cited: 32
Multi-scale modelling reveals that early super-spreader events are a likely contributor to novel variant predominance
Ashish Goyal, Daniel B. Reeves, Joshua T. Schiffer
Journal of The Royal Society Interface (2022) Vol. 19, Iss. 189
Open Access | Times Cited: 25
Increasing contributions of airborne route in SARS-CoV-2 omicron variant transmission compared with the ancestral strain
Shuyi Ji, Shenglan Xiao, Huaibin Wang, et al.
Building and Environment (2022) Vol. 221, pp. 109328-109328
Open Access | Times Cited: 25
Identifiability of parameters in mathematical models of SARS-CoV-2 infections in humans
Stanca M. Ciupe, Necibe Tuncer
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 23
A simple model of COVID-19 explains disease severity and the effect of treatments
Steven Sanche, Tyler Cassidy, P.-H. Chu, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 22
A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions
Rohit Rao, Cynthia J. Musante, Richard Allen
npj Systems Biology and Applications (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 12
Global dynamics of a space-age structured covid-19 model coupling within-host infection and between-host transmission
Peng Wu, Zhaosheng Feng
Communications in Nonlinear Science and Numerical Simulation (2024) Vol. 131, pp. 107801-107801
Closed Access | Times Cited: 4
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
Tin Phan, Carolin Zitzmann, Kara W. Chew, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 4, pp. e1011680-e1011680
Open Access | Times Cited: 4
Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets
Naveen K. Vaidya, Angelica Bloomquist, Alan S. Perelson
Viruses (2021) Vol. 13, Iss. 8, pp. 1635-1635
Open Access | Times Cited: 27
Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021
Michael P. Busch, Susan L. Stramer, Mars Stone, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. Supplement_2, pp. S254-S263
Open Access | Times Cited: 21
SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases
Regina Larionova, K. Byvaltsev, О. А. Кравцова, et al.
Journal of Translational Autoimmunity (2022) Vol. 5, pp. 100154-100154
Open Access | Times Cited: 20

Scroll to top